GlobeNewswire by notified

DBV Technologies to Present New Data at ACAAI 2023

Share

Montrouge, France, November 2, 2023

DBV Technologies to Present New Data at ACAAI 2023

  • New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

A late-breaking oral abstract has been accepted by the ACAAI and will be presented on the interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) trial of Viaskin™ Peanut in peanut-allergic toddlers. The presentation will be available on DBV’s website, www.dbv-technologies.com, following the conclusion of the meeting for those who are unable to attend.

This year’s meeting will also feature a “Product Theater” on Individualizing Peanut Allergy Management: A Case-based Panel Discussion. Drs. Douglas Mack, David Stukus, and Julie Wang will engage in a discussion around the factors influencing peanut allergy management, such as use of food challenges and effects of comorbidities, using various patient scenarios. The Product Theater is scheduled for Saturday, November 11, from 11:35 a.m. to 1:00 p.m. PST.

DBV is sponsoring the 32nd Annual FIT Bowl, a game show-type competition that tests allergy, asthma, and immunology knowledge of participating teams from training programs around the country. The competition is set to be held on Saturday, November 11, from 5:45 p.m. to 7:45 p.m. PST. In addition, DBV is a 2023 ACAAI Benefactor Level Corporate Council Member. The Company will also host a booth in the ACAAI Exhibit Hall from Saturday, November 11 – Monday, November 13th.

“We are very pleased to have a significant presence at ACAAI again this year and add to the growing body of data on the potential of Viaskin Peanut as a new treatment option for peanut-allergic toddlers,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “With no FDA approved treatments, toddlers and their families must practice avoidance, which can be stressful and can significantly impact quality of life. Our goal is to complete the remaining regulatory steps in support of a Biologics License Application (BLA) as quickly and efficiently as possible to potentially bring this novel treatment to these patients in need.”

DBV Abstracts:

Late Breaking Abstract Presentation

“EPOPEX, Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers: 1-year Open-Label Extension to EPITOPE” will be presented by Matthew Greenhawt, M.D., M.Sc., MBA, FACAAI, Children’s Hospital Colorado, Aurora, CO.

  • Abstract ID: LB010
  • Presentation Date: Saturday, November 11
  • Presentation Time: 9:40 a.m. – 9:50 a.m. PST
  • Session/location: Late-breaking Oral Abstracts - Session 1: Food Allergy; Exhibit Hall C – ePoster Area – LIVE Presentation Stage

Viaskin Peanut is the Company’s lead product candidate designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. An investigational, non-invasive, once-daily epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to re-educate the immune system. The safety and efficacy of Viaskin Peanut have not yet been established by the U.S. Food and Drug Administration or the European Medicines Agency.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including, but not limited to, statements regarding the therapeutic potential of Viaskin™ Peanut and EPIT™ and DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or project herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth herein can be found in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission (“SEC”), and future filings and reports made with the AMF and SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Katie Matthews
+ 1 (857) 529-2363
katie.matthews@dbv-technologies.com

Media Contact
Angela Marcucci
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mandatory notification of trade and acceptance by primary insiders11.12.2023 17:12:12 CET | Press release

Reference is made to the stock exchange announcement on 7 December 2023 whereby BW Sirocco Holdings AS (the "Offeror") announced the completion and settlement of the Offer and the acquisition of the Offeror of 30,000,561 shares, representing approximately 95.21% of the total number of shares in BW Ideol AS. The Offeror, being a close associate of Marco Beenen, the chairperson of the board of directors of BW Ideol AS, attach the required notifications of trade to this announcement. Further, mandatory notifications from other primary insiders and their related parties are also attached to this announcement. For further information, please contact: BW Ideol AS Nicolas de Kerangal (Chief Financial & Partnerships Officer) +33 (0) 7 76 87 70 08 / ir@bw-ideol.com (mailto:ir@bw-ideol.com) BW Sirocco Holdings AS Anders S. Platou (Chief Strategy Officer BW Offshore Limited) +47 99 71 86 55 Attachment Project Sirocco - PDMR - Attachments

LambdaTest and Wipro Collaborate for Innovative Gen AI Solutions11.12.2023 17:00:00 CET | Press release

LambdaTest and Wipro forge a pioneering partnership, integrating Wipro’s Gen AI-powered QE capabilities with LambdaTest’s HyperExecute, to revolutionize software testing on the Cloud with advanced AI capabilities. San Francisco , Dec. 11, 2023 (GLOBE NEWSWIRE) -- LambdaTest, a leading cloud-based unified testing platform is partnering with Wipro Limited, a leading technology services and consulting company, to revolutionize software testing by integrating Wipro’s Gen AI powered QE platform IntelliAssure with HyperExecute - a continuous cloud test orchestration solution offered by Lambdatest. The partnership aims to provide organizations that are modernizing and migrating to the cloud with an easy-to-implement, plug-and-play solution for infusing analytics-driven intelligence across their testing lifecycle for improved productivity as well as hyper-accelerated release cycle times. LambdaTest and Wipro's collaborative integration promises cutting-edge capabilities with an aim to enrich t

Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub11.12.2023 16:30:00 CET | Press release

Press Release Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub Nokia Bell Labs is reaffirming its commitment to New Jersey, upholding its 80-year heritage of cutting-edge research and innovation in the state.Move will establish New Brunswick as Nokia’s new R&D hub on the East Coast and affirms Nokia’s commitment to this fast-growing innovation zone in the US. 11 December 2023 New Brunswick, New Jersey – Nokia today announced plans to relocate its campus in Murray Hill, NJ by 2028 to a new state-of-the-art research and development (R&D) facility in the burgeoning innovation and technology hub in New Brunswick, NJ. The new leading-edge R&D facility will propel Nokia Bell Labs to adapt and evolve to remain at the forefront of cutting-edge technology and continue contributing to a legacy of innovation in New Jersey. As the industrial research arm of Nokia, Nokia Bell Labs has always moved ahead of

Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties11.12.2023 16:30:00 CET | Press release

Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Anne Mette Toftegaard, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties. Please see attached report. Contact Please direct any questions regarding this announcement to: Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02 Attachment AS 26 2023 - Report on trading Anne Mette Toftegaard

Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations11.12.2023 16:30:00 CET | Press release

Press Release Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations Nokia Innovation Framework evolving with new venture studio and venture partnerships to unleash the full commercial potential of Nokia Bell Labs technologies outside of Nokia’s strategic perimeters. A new venture studio with America’s Frontier Fund and Roadrunner Venture Studios for commercializing the next generation of critical technology for the US will be situated in New Jersey, the iconic home of Bell Labs innovation for over 80 years.New venture partnership with Celesta Capital will invest in scaling ventures built with deep technologies from Nokia Bell Labs. 11 December 2023 Murray Hill, New Jersey – Nokia today announced an evolution to its Innovation Framework to unlock the full commercial potential of Nokia Bell Labs’ innovations across industries and expand efforts in external startup creation in the US with new partnerships and a new vent